Genomic DNA at specified editing loci (gDNA)

Genomic DNA at specified editing loci refers to the precise sequences within the human genome targeted for therapeutic modification. Unlike traditional drugs that target proteins, gene editing therapies use programmable nucleases—such as CRISPR-Cas9, Zinc Finger Nucleases (ZFNs), and Transcription Activator-Like Effector Nucleases (TALENs)—to recognize and bind to these specific DNA sites (nih.gov, 2024). Once bound, these tools facilitate permanent changes to the genetic code, such as disrupting a disease-causing gene, correcting a mutation, or inserting a functional sequence (wikipedia.org, 2023). This approach is being utilized to treat a wide range of conditions, including hematological disorders like sickle cell disease, where the BCL11A enhancer is targeted to reactivate fetal hemoglobin (crisprtx.com, 2023). However, the use of genomic DNA as a target presents unique challenges, particularly the risk of off-target editing at unintended sites and the potential for large-scale chromosomal rearrangements, which necessitate rigorous safety assessments using next-generation sequencing (fda.gov, 2023; news-medical.net, 2026).

Other names

Nuclear DNAChromosomal DNATarget DNA sequenceGenomic locusTargeted genomic sequence

Site-specific genomic modification via programmable nucleases (CRISPR-Cas9, ZFNs, TALENs) or base/prime editors to induce double-strand breaks or single-nucleotide changes, followed by endogenous DNA repair (NHEJ or HDR) to disrupt, correct, or insert genetic sequences (nih.gov, 2024; patsnap.com, 2025).